Finding off‐targets, biological pathways, and target diseases for chymase inhibitors via structure‐based systems biology approach

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Proteins: Structure, Function, and Bioinformatics

• Publication date

  2015-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/prot.24677PMID 25143259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Density parameter estimation for finding clusters of homologous proteins - tracing actinobacterial pathogenicity lifestyles

  2013cited by this paper
• Coagulation and coagulation signalling in fibrosis.

  2013cited by this paper
• Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic

  2013cited by this paper
• Proteomics-based methods for discovery, quantification, and validation of protein-protein interactions.

  2013cited by this paper
• Data, information, knowledge and principle: back to metabolism in KEGG

  2013cited by this paper
• Recognizing protein-ligand binding sites by global structural alignment and local geometry refinement.

  2012cited by this paper
• The BioGRID interaction database: 2013 update

  2012cited by this paper
• Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

  2012cited by this paper
• Large-scale reverse docking profiles and their applications

  2012cited by this paper
• Direct Thrombin Inhibitors

  2012cited by this paper
• Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.

  2012cited by this paper
• Monospecific Inhibitors Show That Both Mannan-binding Lectin-associated Serine Protease-1 (MASP-1) and -2 Are Essential for Lectin Pathway Activation and Reveal Structural Plasticity of MASP-2*

  2012cited by this paper
• Docking-Based Comparative Intermolecular Contacts Analysis as New 3-D QSAR Concept for Validating Docking Studies and in Silico Screening: NMT and GP Inhibitors as Case Studies

  2011cited by this paper
• Anti‐tumour/metastasis effects of the potassium‐sparing diuretic amiloride: An orally active anti‐cancer drug waiting for its call‐of‐duty?

  2011cited by this paper
• Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region.

  2011cited by this paper
• A tick salivary protein targets cathepsin G and chymase and inhibits host inflammation and platelet aggregation.

  2011cited by this paper
• Direct thrombin inhibitors.

  2011cited by this paper
• Metformin in prostate cancer: two for the price of one.

  2011cited by this paper
• Potency variation of small-molecule chymase inhibitors across species.

  2010cited by this paper
• Inhibition of Factor XIa as a New Approach to Anticoagulation

  2010cited by this paper
• Significance of Chymase-Dependent Matrix Metalloproteinase-9 Activation on Indomethacin-Induced Small Intestinal Damages in Rats

  2010cited by this paper
• A Multidimensional Strategy to Detect Polypharmacological Targets in the Absence of Structural and Sequence Homology

  2010cited by this paper
• SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison

  2010cited by this paper
• Outcomes of Thrombolysis for Acute Ischemic Stroke in Octogenarians Versus Nonagenarians

  2010cited by this paper
• Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment.

  2010cited by this paper
• Therapeutic potential of complement modulation

  2010cited by this paper
• Complement and periodontitis.

  2010cited by this paper
• Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109

  2010cited by this paper
• The BioGRID Interaction Database: 2011 update

  2010cited by this paper
• Predicting new molecular targets for known drugs

  2009cited by this paper
• The many causes of severe congenital neutropenia.

  2009cited by this paper
• The Amyloid Precursor Protein/Protease Nexin 2 Kunitz Inhibitor Domain Is a Highly Specific Substrate of Mesotrypsin*

  2009cited by this paper
• AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

  2009cited by this paper
• Diversity and Complexity in DNA Recognition by Transcription Factors

  2009cited by this paper
• Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network To Explain the Side Effects of CETP Inhibitors

  2009cited by this paper
• Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis

  2009cited by this paper
• A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery

  2009cited by this paper
• Nucleophosmin Is Cleaved and Inactivated by the Cytotoxic Granule Protease Granzyme M during Natural Killer Cell-mediated Killing*

  2009cited by this paper
• Possible roles of mast cell-derived chymase for skin rejuvenation

  2009cited by this paper
• Role of neutrophil proteinase 3 and mast cell chymase in chemerin proteolytic regulation

  2008cited by this paper
• Genotype-phenotype associations between chymase and angiotensin—converting enzyme gene polymorphisms in chronic systolic heart failure patients

  2008cited by this paper
• Network pharmacology: the next paradigm in drug discovery.

  2008cited by this paper
• Human Protein Reference Database—2009 update

  2008cited by this paper
• Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade

  2008cited by this paper
• Drug Target Identification Using Side-Effect Similarity

  2008cited by this paper
• Practical Hemostasis and Thrombosis

  2008cited by this paper
• The role of complement in inflammatory diseases from behind the scenes into the spotlight.

  2007cited by this paper
• 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.

  2007cited by this paper
• Identification of a novel inhibitor of urokinase-type plasminogen activator

  2007cited by this paper
• Drug—target network

  2007cited by this paper
• Structure-based drug design: docking and scoring.

  2007cited by this paper
• How to design multi-target drugs

  2007cited by this paper
• Measuring semantic similarity between Gene Ontology terms

  2007cited by this paper
• Structure‐based virtual ligand screening with LigandFit: Pose prediction and enrichment of compound collections

  2007cited by this paper
• Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study.

  2007cited by this paper
• Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment

  2006cited by this paper
• MINT: the Molecular INTeraction database

  2006cited by this paper
• Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more

  2006cited by this paper
• Human Mast Cell Chymase Cleaves Pro-IL-18 and Generates a Novel and Biologically Active IL-18 Fragment1

  2006cited by this paper
• Strategies for optimizing combinations of molecularly targeted anticancer agents

  2006cited by this paper
• Development and validation of a modular, extensible docking program: DOCK 5

  2006cited by this paper
• Targeting proteases: successes, failures and future prospects

  2006cited by this paper
• Gene functional similarity search tool (GFSST)

  2006cited by this paper
• A small molecule–kinase interaction map for clinical kinase inhibitors

  2005cited by this paper
• Molecular mechanisms of fibrinolysis

  2005cited by this paper
• Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.

  2005cited by this paper
• Strategies for targeting protein-protein interactions with synthetic agents.

  2005cited by this paper
• Inhibition of Transforming Growth Factor- βActivation is a Novel Effect of Chymase Inactivation

  2005cited by this paper
• A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo*

  2005cited by this paper
• Fibrinogen and fibrin structure and functions

  2005cited by this paper
• Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41.

  2005cited by this paper
• A Novel, Potent Dual Inhibitor of the Leukocyte Proteases Cathepsin G and Chymase

  2005cited by this paper
• Human protein reference database—2006 update

  2005cited by this paper
• Adenoviral Gene Delivery of Elafin and Secretory Leukocyte Protease Inhibitor Attenuates NF-κB-Dependent Inflammatory Responses of Human Endothelial Cells and Macrophages to Atherogenic Stimuli1

  2004cited by this paper
• The efficiency of multi-target drugs: the network approach might help drug design.

  2004cited by this paper
• Human Mesotrypsin Is a Unique Digestive Protease Specialized for the Degradation of Trypsin Inhibitors*

  2003cited by this paper
• Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease.

  2003cited by this paper
• LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites.

  2003cited by this paper
• Improved protein–ligand docking using GOLD

  2003cited by this paper
• Tissue factor pathway inhibitor is highly susceptible to chymase-mediated proteolysis.

  2003cited by this paper
• Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients.

  2002cited by this paper
• Molecular Basis of a Selective C1s Deficiency Associated with Early Onset Multiple Autoimmune Diseases1

  2001cited by this paper
• Design, synthesis and pharmacological evaluation of 3-benzylazetidine-2-one-based human chymase inhibitors.

  2001cited by this paper
• The Restricted Expression of Granzyme M in Human Lymphocytes1

  2001cited by this paper
• Mast cells mediate complement activation after acid aspiration.

  2001cited by this paper
• Structure-activity relationship studies of chloromethyl ketone derivatives for selective human chymase inhibitors.

  2000cited by this paper
• Degradation of outer membrane protein A in Escherichia coli killing by neutrophil elastase.

  2000cited by this paper
• Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.

  2000cited by this paper
• Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.

  1999cited by this paper
• Selective complement C1s deficiency caused by homozygous four-base deletion in the C1s gene

  1998cited by this paper
• Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs

  1998cited by this paper
• Blood clotting in minimally altered whole blood.

  1996cited by this paper
• Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming.

  1995cited by this paper
• Thrombin is inactivated by mast cell secretory granule chymase.

  1993cited by this paper
• The FASEB Journal express article 10.1096/fj.01-0486fje. Published online October 29, 2001. Regulation of extravascular coagulation and fibrinolysis by heparin-dependent mast cell chymase

  year unknowncited by this paper

• Structure-Guided Design and in Vivo Validation of a VP4-Derived Subunit Vaccine Candidate against Bovine Rotavirus.

  2025cites this paper
• Experimental and calculation study of co-delivery of insulin and nitric oxide carriers for diabetes and cardiovascular diseases

  2025cites this paper
• Identification of potential MMP-8 inhibitors through virtual screening of natural product databases

  2025cites this paper
• In-silico Approach to Combat Methicillin-resistant Staphylococcus aureus: Targeting RelP Protein with Inhibitor Peptide to Mitigate Drug Resistance.

  2025cites this paper
• DFT and dynamic simulations of OleuoPectin structures as a potential anticoagulant agent

  2025cites this paper
• Integrative machine learning and molecular simulation approaches identify GSK3β inhibitors for neurodegenerative disease therapy

  2025cites this paper
• Theoretical studies of arbutin, glutathione, and sea cucumber extracts as inhibitors of tyrosinase

  2025cites this paper
• Integrated computational and experimental evaluation of grossamide as a natural product scaffold for dual carbohydrase inhibition in diabetes

  2025cites this paper
• Identification of STAT3 phosphorylation inhibitors using generative deep learning, virtual screening, molecular dynamics simulations, and biological evaluation for non-small cell lung cancer therapy

  2024cites this paper
• DAEM: Deep attributed embedding based multi-task learning for predicting adverse drug-drug interaction

  2022cites this paper
• Adeno-associated virus 9 vector-mediated cardiac-selective expression of human secretory leukocyte protease inhibitor attenuates myocardial ischemia/reperfusion injury

  2022cites this paper
• Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury

  2021cites this paper
• Prevention of Post-Operative Adhesions: A Comprehensive Review of Present and Emerging Strategies

  2021cites this paper
• Intravital multiphoton microscopy as a novel tool in the field of immunopharmacology.

  2020cites this paper
• Plant Chemical Genetics: From Phenotype-Based Screens to Synthetic Biology[OPEN]

  2017cites this paper
• In silico methods to address polypharmacology: current status, applications and future perspectives.

  2016cites this paper
• Harnessing Polypharmacology with Computer-Aided Drug Design and Systems Biology.

  2016cites this paper
• Endomembrane trafficking and brassinosteroid signaling from a small molecule perspective

  2015cites this paper